×
About 5,267 results

ALLMedicine™ Hyperkalemia Center

Research & Reviews  2,149 results

The pharmacotherapeutic management of hyperkalemia in patients with cardiovascular dise...
https://doi.org/10.1080/14656566.2021.1891223
Expert Opinion on Pharmacotherapy; Tamargo J, Caballero R et. al.

Feb 23rd, 2021 - Introduction: Patients with cardiovascular diseases (CVD) are at increased risk of hyperkalemia, particularly when treated with renin-angiotensin-aldosterone inhibitors (RAASIs). Because the occurrence or fear of hyperkalemia, RAASIs are frequentl...

Ambulatory Treatments for RAAS Inhibitor-Related Hyperkalemia and the 1-Year Risk of Re...
https://doi.org/10.2215/CJN.12990820
Clinical Journal of the American Society of Nephrology : ... Hundemer GL, Talarico R et. al.

Feb 20th, 2021 - The optimal ambulatory management of renin-angiotensin-aldosterone system inhibitor (RAASi)-related hyperkalemia to reduce the risk of recurrence is unknown. We examined the risk of hyperkalemia recurrence on the basis of outpatient pharmacologic ...

Incidence, characteristics, and outcomes among inpatient, outpatient, and emergency dep...
https://doi.org/10.1515/cclm-2020-1476
Clinical Chemistry and Laboratory Medicine; Kuo WH, You HL et. al.

Feb 19th, 2021 - Severe hyperkalemia can cause life-threatening arrhythmia, cardiac arrest, or death. This study aimed to investigate the incidence and the associated factors relevant to critical hyperkalemia (≥6 mmol/L) among inpatients, outpatients, and emergenc...

Management of RAASi-associated hyperkalemia in patients with cardiovascular disease.
https://doi.org/10.1007/s10741-020-10069-3 10.1093/eurheartj/ehw128 10.1093/ehjcvp/pvy015 10.1016/j.jacc.2016.06.060 10.1161/circheartfailure.114.001104 10.1159/000479802 10.1016/j.repc.2020.03.015 10.1002/ejhf.1182 10.1002/ejhf.1199 10.1002/ejhf.1079 10.1001/jama.2014.15688 10.1016/s0140-6736(19)32135-x
Heart Failure Reviews; Silva-Cardoso J, Brito D et. al.

Feb 18th, 2021 - Renin-angiotensin-aldosterone system inhibitors (RAASi) reduce morbidity and mortality in heart failure (HF) with reduced ejection fraction in a dose-dependent manner. They also have a positive impact in other cardiovascular diseases (CVDs). Howev...

Dietary Salt Modifies the Blood Pressure Response to Renin-Angiotensin Inhibition in Ex...
https://doi.org/10.1152/ajprenal.00603.2020
American Journal of Physiology. Renal Physiology; Bovee DM, Uijl E et. al.

Feb 15th, 2021 - Chronic kidney disease (CKD) contributes to hypertension, but the mechanisms are incompletely understood. To address this, we applied the 5/6th nephrectomy rat model to characterize hypertension and the response to dietary salt and renin-angiotens...

see more →

Drugs  171 results see all →

Clinicaltrials.gov  2,599 results

The pharmacotherapeutic management of hyperkalemia in patients with cardiovascular dise...
https://doi.org/10.1080/14656566.2021.1891223
Expert Opinion on Pharmacotherapy; Tamargo J, Caballero R et. al.

Feb 23rd, 2021 - Introduction: Patients with cardiovascular diseases (CVD) are at increased risk of hyperkalemia, particularly when treated with renin-angiotensin-aldosterone inhibitors (RAASIs). Because the occurrence or fear of hyperkalemia, RAASIs are frequentl...

Ambulatory Treatments for RAAS Inhibitor-Related Hyperkalemia and the 1-Year Risk of Re...
https://doi.org/10.2215/CJN.12990820
Clinical Journal of the American Society of Nephrology : ... Hundemer GL, Talarico R et. al.

Feb 20th, 2021 - The optimal ambulatory management of renin-angiotensin-aldosterone system inhibitor (RAASi)-related hyperkalemia to reduce the risk of recurrence is unknown. We examined the risk of hyperkalemia recurrence on the basis of outpatient pharmacologic ...

Incidence, characteristics, and outcomes among inpatient, outpatient, and emergency dep...
https://doi.org/10.1515/cclm-2020-1476
Clinical Chemistry and Laboratory Medicine; Kuo WH, You HL et. al.

Feb 19th, 2021 - Severe hyperkalemia can cause life-threatening arrhythmia, cardiac arrest, or death. This study aimed to investigate the incidence and the associated factors relevant to critical hyperkalemia (≥6 mmol/L) among inpatients, outpatients, and emergenc...

Management of RAASi-associated hyperkalemia in patients with cardiovascular disease.
https://doi.org/10.1007/s10741-020-10069-3 10.1093/eurheartj/ehw128 10.1093/ehjcvp/pvy015 10.1016/j.jacc.2016.06.060 10.1161/circheartfailure.114.001104 10.1159/000479802 10.1016/j.repc.2020.03.015 10.1002/ejhf.1182 10.1002/ejhf.1199 10.1002/ejhf.1079 10.1001/jama.2014.15688 10.1016/s0140-6736(19)32135-x
Heart Failure Reviews; Silva-Cardoso J, Brito D et. al.

Feb 18th, 2021 - Renin-angiotensin-aldosterone system inhibitors (RAASi) reduce morbidity and mortality in heart failure (HF) with reduced ejection fraction in a dose-dependent manner. They also have a positive impact in other cardiovascular diseases (CVDs). Howev...

Hydrochlorothiazide - hydrochlorothiazide capsule-NuCare Pharmaceuticals,Inc.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8157258d-465c-1592-e053-2991aa0a25ec

Feb 16th, 2021 - Hydrochloro­thiazide capsules USP are indicated in the management of hypertension either as the sole therapeutic agent, or in combination with other antihypertensives. Unlike potassium sparing combina­tion diuretic products, hydrochloro­thiazide c...

see more →

News  347 results

Dapagliflozin Halves Hyperkalemia in Some HF Patients
https://www.staging.medscape.com/viewarticle/940012

Oct 28th, 2020 - For patients with heart failure with reduced ejection fraction (HFrEF), the addition of dapagliflozin (Farxiga) to a mineralocorticoid receptor antagonist (MRA) halved the incidence of moderate to severe hyperkalemia, a prespecified analysis of DA...

Dapagliflozin Halves Hyperkalemia in Some HF Patients
https://www.medscape.com/viewarticle/940012

Oct 28th, 2020 - For patients with heart failure with reduced ejection fraction (HFrEF), the addition of dapagliflozin (Farxiga) to a mineralocorticoid receptor antagonist (MRA) halved the incidence of moderate to severe hyperkalemia, a prespecified analysis of DA...

Novel Drug Slows Progression of Diabetic Kidney Disease
https://www.staging.medscape.com/viewarticle/939724

Oct 22nd, 2020 - For patients with diabetic kidney disease, finerenone, an agent from a new class of selective, nonsteroidal mineralocorticoid receptor antagonists, led to significant reductions in combined adverse renal outcomes and in combined adverse cardiovasc...

Novel Drug Slows Progression of Diabetic Kidney Disease
https://www.medscape.com/viewarticle/939724

Oct 22nd, 2020 - For patients with diabetic kidney disease, finerenone, an agent from a new class of selective, nonsteroidal mineralocorticoid receptor antagonists, led to significant reductions in combined adverse renal outcomes and in combined adverse cardiovasc...

Will Mineralocorticoid Receptor Antagonists Move Higher Up the Hypertension Treatment Pathway?
https://www.staging.medscape.com/viewarticle/936725

Sep 3rd, 2020 - Mineralocorticoid receptor antagonists (MRAs) are still finding their place in nephrology. Many of us relegate them to the bottom of our therapeutic bag for use only after we've exhausted other renin-angiotensin-aldosterone (RAAS)-modifying agents...

see more →

Patient Education  1 results see all →